11:25 AM EST - Satellos Bioscience Inc. : Announced the submission of an Investigational New Drug application to the U.S. Food and Drug Administration, along with parallel regulatory filings in the United Kingdom, Europe, Serbia and Australia, to initiate a Phase 2 clinical trial of SAT-3247 in ambulatory children with Duchenne muscular dystrophy (Duchenne or DMD). Satellos Bioscience Inc.
shares T.MSCL are trading up $0.02 at $0.65.
